Stock Futures Show Modest Movement, S&P 500 Futures Up 0.01%
Stock futures are showing modest movement, reflecting a pause after recent record highs. Traders appear reluctant to push markets sharply higher without fresh near-term catalysts, especially as they look ahead to key economic data including employment reports later this week.Despite the restraint in equity moves, commodities and precious metals remain supportive for markets. Oil prices have resumed their climb and both gold and silver futures are extending gains amid ongoing geopolitical tension and macro uncertainty. Meanwhile, technology stocks are getting fresh attention around the CES 2026 trade show, with new AI chip announcements contributing to sector confidence, even as investors balance that optimism with caution.In pre-market trading, S&P 500 futures rose 0.01%, Nasdaq futures rose 0.16% and Dow futures fell 0.06%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Aevaup 28% after announcing 4D LiDAR integration within NvidiaDrive HyperionOneStreamup 27% after BloombergHg is in advanced talks to acquire the companyOculisup 8% after Privosegtor was granted breakthrough therapy designation by the FDAZeta Globalup 8% after announcing a strategic collaboration with OpenAIMicrochipup 4% after raising its Q3 revenue guidanceVistraup 4% after agreeing to acquire Cogentrix Energy for $4BLOWER -Madrigal Pharmaceuticalsdown 2% after Wolfe Research downgraded the stock to Peer Perform and removed the firm's prior $579 price targetWeavedown 1% after Raymond James downgraded shares to Outperform from Strong Buy with a price target of $10, down from $12Lennardown 1% after UBS downgraded the stock to Neutral with a price target of $122, down from $137D.R. Hortondown 1% after Wells Fargo downgraded shares to Equal Weight with a price target of $155, down from $180
Trade with 70% Backtested Accuracy
Analyst Views on OCS
About OCS
About the author

- Current Treatment Landscape: Diabetic macular edema (DME) primarily affects individuals around the age of 52, with 60% of patients remaining untreated one year post-diagnosis, indicating significant gaps in current treatment approaches that hinder vision recovery opportunities.
- DME AWARE Findings: The DME AWARE Delphi study underscores the critical need for non-invasive treatment options, with experts reaching consensus on prioritizing eye drops for early intervention to improve visual function and reduce inflammatory factors.
- Potential of OCS-01: Oculis's OCS-01 eye drops are in Phase 3 trials and, if successful, could become the first non-invasive treatment for DME, offering a new option for the 40% of patients who inadequately respond to existing injection therapies.
- Global Expert Consensus: The DME AWARE study, involving 25 leading retina and ophthalmology experts, established a global consensus on the urgent need for non-invasive therapies and early intervention in DME management, potentially driving transformative changes in future clinical practices.
- Study Findings Presentation: Oculis will present the latest findings from the DME AWARE Delphi study at the 2026 ARVO Annual Meeting, emphasizing the urgent need for non-invasive treatment options to enhance care for diabetic macular edema patients.
- Clinical Progress Update: CEO Riad Sherif announced that the final patient visit for the Phase 3 DIAMOND study of OCS-01 eye drops has been completed, with pivotal topline results expected in June 2026, potentially redefining treatment paradigms for diabetic macular edema.
- Privosegtor's Potential: The Phase 2 ACUITY trial of Privosegtor in patients with acute optic neuritis demonstrated neuroprotective effects, indicating its potential to become the first neuroprotective therapy for optic neuritis, with broad applicability in other neuro-ophthalmic diseases.
- Global Impact: Oculis' research and product development not only target diabetic macular edema but also encompass other neuro-ophthalmic conditions, highlighting the company's strategic importance in addressing significant unmet medical needs worldwide.
- Clinical Trial Progress: Oculis Holding AG announced the completion of the final patient visit in the Phase 3 DIAMOND program for OCS-01, with topline results expected in June 2026, marking a significant advancement in the treatment of diabetic macular edema.
- Patient Recruitment: The DIAMOND program consists of two randomized, double-masked, multicenter trials, enrolling over 800 patients who were randomized to receive either OCS-01 or a vehicle, demonstrating the company's extensive engagement in clinical research and commitment to patient needs.
- Market Potential Analysis: In the U.S., approximately 1.8 million people are diagnosed with diabetic macular edema, with about 1 million remaining untreated, indicating a substantial market opportunity for Oculis to address the underserved patient population.
- Strong Financial Position: As of December 31, Oculis reported $268.7 million in cash and short-term investments, with an expected cash runway extending into 2029, reflecting the company's financial stability for ongoing research and market initiatives.
- Trial Completion: The final patient visit for OCS-01's DIAMOND program, involving over 800 patients, has been completed, with topline results expected in June 2026, marking a significant advancement in the treatment of diabetic macular edema (DME) and potentially transforming existing treatment paradigms.
- Significant Market Need: In the U.S., approximately 1 million DME patients remain untreated, highlighting the urgent demand for early intervention and new therapies; OCS-01, as the first non-invasive topical treatment, could fill this market gap, with an estimated market size of $3 billion.
- Efficacy Demonstrated: In the first stage of the DIAMOND program, OCS-01 showed significant improvements in visual acuity and rapid edema reduction, further validating its potential as a treatment for DME, particularly for patients inadequately served by current therapies.
- Future Development Outlook: Oculis plans to submit a New Drug Application (NDA) in Q4 2026 and continues to advance other clinical projects, indicating the company's commitment to addressing significant unmet medical needs in the ophthalmology sector.
- Clinical Trial Progress: Oculis's OCS-01 is on track to release pivotal Phase 3 trial results for diabetic macular edema (DME) in June 2026, which will solidify the company's leadership position in the ophthalmology sector.
- Precision Medicine Innovation: Licaminlimab is being evaluated as the first genotype-based development program for dry eye disease (DED), with topline results expected by late 2026, marking a significant breakthrough in precision medicine that could transform treatment paradigms for DED.
- Market Opportunity: Privosegtor has received Breakthrough Therapy designation from the FDA and Priority Medicines designation from the EMA for optic neuritis (ON), advancing its registrational program with a potential market opportunity exceeding $7 billion in the U.S., highlighting Oculis's substantial market potential in neuro-ophthalmology.
- Financial Robustness: With a strong balance sheet and a rich clinical pipeline, Oculis is positioned to deliver six pivotal readouts with current funding, further advancing its mission to innovate in eye care and neuro-ophthalmology.
- Regulatory Support Strengthened: Oculis's Privosegtor has received PRIME designation from the EMA, following the FDA's Breakthrough Therapy designation, indicating its potential in treating optic neuritis and possibly accelerating its global development process.
- Clinical Trial Results Promising: The ACUITY Phase 2 trial demonstrated significant improvements in low-contrast visual acuity with Privosegtor combined with steroids, reinforcing its efficacy as a neuroprotective treatment and addressing urgent needs for optic neuritis patients.
- Significant Market Opportunity: The potential market opportunity for optic neuritis is estimated at $7 billion, and as the first neuroprotective therapy, Privosegtor could fill this gap, meeting the current lack of effective treatments.
- Global Registration Program Advancing: Oculis is advancing the PIONEER registration program, which includes three global registrational trials in optic neuritis and non-arteritic anterior ischemic optic neuropathy, further validating Privosegtor's clinical application potential.








